Medivation Announces Participation at Two Upcoming Investor Conferences
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 09/23/11 -- Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following two investor conferences:
The JMP Securities Healthcare Conference on September 27 at 1:30pm Eastern Time at the St. Regis Hotel in New York City
The NewsMakers in the Biotech Industry Conference on October 21 at 9:30am Eastern Time at the Millennium Broadway Hotel in New York City
Dr. Hung will provide an overview of Medivation and its clinical development programs. A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at . A replay also will be available for 30 days following the live presentation.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at .
Contacts:
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101
Anne Bowdidge
Investor Relations
(650) 218-6900
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.09.2011 - 20:00 Uhr
Sprache: Deutsch
News-ID 69079
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 254 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medivation Announces Participation at Two Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Medivation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
